Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor - PubMed
doi: 10.1158/1535-7163.MCT-08-1008. Epub 2009 May 5.
Kerrington D Smith, Quan-Sheng Zhu, Jun Liu, Ian E McCutcheon, John M Slopis, Funda Meric-Bernstam, Zhenghong Peng, William G Bornmann, Gordon B Mills, Alexander J Lazar, Raphael E Pollock, Dina Lev
Affiliations
- PMID: 19417153
- DOI: 10.1158/1535-7163.MCT-08-1008
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor
Changye Y Zou et al. Mol Cancer Ther. 2009 May.
Abstract
The mammalian target of rapamycin (mTOR) pathway may constitute a potential target for the treatment of malignant peripheral nerve sheath tumors (MPNST). However, investigations of other cancers suggest that mTOR blockade can paradoxically induce activation of prosurvival, protumorigenic signaling molecules, especially upstream AKT. Consequently, we hypothesized that dual phosphatidylinositol 3-kinase (PI3K)/AKT-mTOR blockade might be applicable for MPNST treatment. Expression of activated mTOR downstream targets (p4EBP1 and pS6RP) and pAKT was evaluated immunohistochemically in a tissue microarray of human MPNSTs (n = 96) and benign neurofibromas (n = 31). Results were analyzed by Wilcoxon rank-sum tests. mTOR and AKT pathways in human MPNST cell lines, and the effects of rapamycin (mTOR inhibitor), LY294002 (dual PI3K/mTOR inhibitor), and PI-103 (potent dual PI3K/AKT-mTOR inhibitor) on pathway activation were evaluated by Western blot. Effects on cell growth were evaluated via MTS and colony formation assays. Cell cycle progression and apoptosis were assessed by propidium iodide/fluorescence-activated cell sorting staining and Annexin V assays. Acridine orange staining/fluorescence-activated cell sorting analysis, electron microscopy, and Western blot evaluated autophagy induction. p4EBP1, pS6Rp, and pAKT levels were found to be significantly higher in MPNST versus neurofibroma (P < 0.05 for all markers). mTOR and AKT pathways were found to be highly activated in MPNST cell lines. MPNST cells were sensitive to rapamycin; however, rapamycin enhanced pAKT and peIF4E expression. PI-103 abrogated MPNST cell growth and induced G(1) cell cycle arrest potentially through repression of cyclin D1. PI-103 did not elicit apoptosis but significantly induced autophagy in MPNST cells. These results suggest further study of combined PI3K/AKT and mTOR inhibition as a novel therapy for patients harboring MPNST.
Similar articles
-
Verhees F, Demers I, Legemaate D, Jacobs R, Hoeben A, Kremer B, Speel EJ. Verhees F, et al. Int J Oncol. 2025 Feb;66(2):13. doi: 10.3892/ijo.2025.5719. Epub 2025 Jan 10. Int J Oncol. 2025. PMID: 39791215 Free PMC article.
-
Tanaka Y, Amano T, Nakamura A, Yoshino F, Takebayashi A, Takahashi A, Yamanaka H, Inatomi A, Hanada T, Yoneoka Y, Tsuji S, Murakami T. Tanaka Y, et al. Hum Reprod. 2024 May 11;39(7):1519-32. doi: 10.1093/humrep/deae085. Online ahead of print. Hum Reprod. 2024. PMID: 38734930 Free PMC article.
-
Huang T, Zhang Y, Wu Y, Han X, Li L, Guo Z, Li K, Xin Y, Wang W. Huang T, et al. Saudi J Gastroenterol. 2024 Nov 1;30(6):381-388. doi: 10.4103/sjg.sjg_169_24. Epub 2024 Sep 9. Saudi J Gastroenterol. 2024. PMID: 39246119 Free PMC article.
-
Melatonin effect on breast and ovarian cancers by targeting the PI3K/Akt/mTOR pathway.
Pourbarkhordar V, Rahmani S, Roohbakhsh A, Hayes AW, Karimi G. Pourbarkhordar V, et al. IUBMB Life. 2024 Dec;76(12):1035-1049. doi: 10.1002/iub.2900. Epub 2024 Aug 30. IUBMB Life. 2024. PMID: 39212097 Review.
-
Zhang L, Wu J, Ling MT, Zhao L, Zhao KN. Zhang L, et al. Mol Cancer. 2015 Apr 17;14:87. doi: 10.1186/s12943-015-0361-x. Mol Cancer. 2015. PMID: 26022660 Free PMC article. Review.
Cited by
-
Zhang X, Hu C, Li D, Liu S. Zhang X, et al. Hum Cell. 2024 Jan;37(1):345-355. doi: 10.1007/s13577-023-01000-7. Epub 2023 Nov 8. Hum Cell. 2024. PMID: 37938540
-
Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, Pollock RE, Lev D. Ghadimi MP, et al. Mol Cancer Ther. 2012 Aug;11(8):1758-69. doi: 10.1158/1535-7163.MCT-12-0015. Epub 2012 Jul 30. Mol Cancer Ther. 2012. PMID: 22848094 Free PMC article.
-
Castellsagué J, Gel B, Fernández-Rodríguez J, Llatjós R, Blanco I, Benavente Y, Pérez-Sidelnikova D, García-Del Muro J, Viñals JM, Vidal A, Valdés-Mas R, Terribas E, López-Doriga A, Pujana MA, Capellá G, Puente XS, Serra E, Villanueva A, Lázaro C. Castellsagué J, et al. EMBO Mol Med. 2015 May;7(5):608-27. doi: 10.15252/emmm.201404430. EMBO Mol Med. 2015. PMID: 25810463 Free PMC article.
-
Slopis JM, Arevalo O, Bell CS, Hebert AA, Northrup H, Riascos RF, Samuels JA, Smith KC, Tate P, Koenig MK. Slopis JM, et al. Drugs R D. 2018 Dec;18(4):295-302. doi: 10.1007/s40268-018-0248-6. Drugs R D. 2018. PMID: 30284154 Free PMC article. Clinical Trial.
-
Torres KE, Liu J, Young E, Huang KL, Ghadimi M, Lusby K, Lazar AJ, Lev D. Torres KE, et al. Histopathology. 2011 Jul;59(1):156-9. doi: 10.1111/j.1365-2559.2011.03867.x. Histopathology. 2011. PMID: 21771036 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous